Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events?

Featuring John Koo, MD | ProfessorUCSF Department of DermatologyUSCF Psoriasis Treatment CenterSan Francisco, CA | Published October 14, 2021